ImmunoGen, Inc.: directors' dealings · United States · SEC (Form 4)

About ImmunoGen, Inc.

ImmunoGen, Inc. was a U.S. biopharmaceutical company focused on antibody-drug conjugates (ADCs), a highly targeted cancer-therapy modality that combines antibody precision with potent cytotoxic payload delivery. Founded in Massachusetts in 1981, the company built its identity over decades around oncology research and development. Its headquarters were in Waltham, Massachusetts, United States, and its shares traded on the NASDAQ under the ticker IMGN prior to the acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000104746910007750/a2199944z10-k.htm?utm_source=openai)) Operationally, ImmunoGen concentrated on developing and commercializing ADC-based treatments for cancers with significant unmet medical need. Its flagship asset was ELAHERE (mirvetuximab soravtansine-gynx), an oncology therapy designed for patients with FRα-positive ovarian cancer. Beyond the lead product, the company also maintained a pipeline of next-generation ADC candidates, which gave ImmunoGen the profile of a technology platform company rather than a single-asset biotech. In market materials, ImmunoGen was described as a leader in the expanding field of ADCs for cancer treatment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000155837023007145/imgn-20230428xex99d1.htm?utm_source=openai)) From a competitive standpoint, ImmunoGen occupied a meaningful niche in the highly competitive oncology landscape, where large pharmaceutical groups and specialized ADC developers constantly vie for clinical differentiation, regulatory success, and commercial share. The company’s investment case was anchored in three elements: the clinical and commercial promise of ELAHERE, the credibility of its ADC platform, and the optionality embedded in follow-on pipeline assets. That combination gave ImmunoGen a reputation as a scientifically credible but mid-sized oncology platform with asymmetric upside if its lead program performed well. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000155837023007145/imgn-20230428xex99d1.htm?utm_source=openai)) The most important recent corporate development was AbbVie’s acquisition of ImmunoGen. AbbVie announced the transaction in late 2023, valuing ImmunoGen at about $10.1 billion, and completed the acquisition on February 12, 2024. AbbVie said the deal would strengthen its solid-tumor oncology franchise and add ELAHERE plus ImmunoGen’s next-generation ADC pipeline to its broader portfolio. As a result, ImmunoGen is no longer an independent listed company, but its historic filings remain relevant for investors analyzing legacy SEC Form 4 insider transactions and the company’s pre-acquisition operating history. ([investors.abbvie.com](https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy?utm_source=openai)) In short, ImmunoGen was a precision-oncology biotech with a high-risk/high-reward profile, centered on ADC science and a commercially important lead asset. For French-speaking investors, it is also a good example of how innovative U.S. biotech companies listed on NASDAQ in the United States are often consolidated by larger pharmaceutical players once a lead product proves its strategic value. ([investors.abbvie.com](https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy?utm_source=openai))